Skip to Main content Skip to Navigation
Journal articles

Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.

Abstract : For this patient population, low dose metronomic cyclophosphamide prednisolone might be a viable alternative. Its convenient oral administration, low cost, and lack of toxicity justify further studies alone, or in combination with other agents in HRPC patients.
Document type :
Journal articles
Complete list of metadatas

https://www.hal.inserm.fr/inserm-00555027
Contributor : Grégoire Mignot <>
Submitted on : Wednesday, January 12, 2011 - 9:17:19 AM
Last modification on : Wednesday, June 10, 2020 - 2:06:49 PM

Identifiers

  • HAL Id : inserm-00555027, version 1
  • PUBMED : 21036758

Citation

Sylvain Ladoire, Jean-Christophe Eymard, Sylvie Zanetta, Grégoire Mignot, Etienne Martin, et al.. Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.. Anticancer Research, International Institute of Anticancer Research, 2010, 30 (10), pp.4317-23. ⟨inserm-00555027⟩

Share

Metrics

Record views

216